In 2009 Andrea Alexander adopted twins. The catch is, she also gave birth to them.

Alexander’s husband is infertile, and traditional adoption wasn’t a viable option so they decided to use embryos from another family to build their own.

Alexander started researching frozen embryo donations specifically for families hoping to adopt. She contacted the religious embryo adoption agency, Snowflake, and began the process, which included a home study, a full medical background check of the donating family, and photos of their children.

Cora and Max were created in 2006, adopted in 2009 and born in 2010.

With the IVF success rate, there is a surplus of more than 600,000 frozen embryos in the United States.

Fertility patients are split over what to do with their unused embryos. According to a recent study reported on ABC News, 54% want to keep them frozen for future use, 21% want them donated to research, and 7% want them donated to another couple.

As a Catholic Alexander’s choice came with challenges, which is a dilemma many patients of faith must face and come to terms with.

The Catholic Church states that human life should not be created in a laboratory and is cautions against embryo adoption. Ultimately Alexander continued with the procedure.

She hopes to go through embryo adoption again. She has limited communication with the children’s genetic parents. At many fertility clinics, though, embryo donations are anonymous.

Lead investigators are Aritro Sen, PhD, Research Assistant Professor, and Stephen R. Hammes, MD, PhD, Professor, both in the Division of Endocrinology and Metabolism at URSMD and who have published pioneering work on the subject in a rodent model; and Norbert Gleicher, MD, CHR’s Chief Scientist, and David H. Barad, MD, MS, Senior Scientist at CHR, who by introducing the androgen dehydroepiandrosterone (DHEA) into infertility treatment have revolutionized the treatment of women with low ovarian reserve worldwide.

“The goal of this research collaboration is to combine complementary animal and laboratory expertise at URSMD with clinical expertise at CHR,” explains Dr. Gleicher. “By combining research in URSMD’s unique animal model and CHR’s large clinical human experience, we aim to better understand how DHEA, as well as other androgens, improves female fertility.”

“This is a very exciting development,” adds Dr. Barad. “We have known for years now that DHEA improves pregnancy chances but only very recently learned that this very likely occurs through conversion of DHEA to testosterone. For all practical purposes, this means that the process very likely involves the androgen receptor (AR) on granulosa cells.” Dr. Barad continues: “For this kind of work, our colleagues at URSMD have the ideal mouse model.”

Dr. Sen, who will become a Visiting Assistant Scientist at CHR, chimes in: “we are very much looking forward to this collaboration, which should be very beneficial for both institutions.”

About Center for Human Reproduction
Center for Human Reproduction (CHR, http://www.centerforhumanreprod.com) is a leading fertility center in New York City with a worldwide reputation as a “fertility center of last resort,” offering cutting-edge, research-based treatment options to infertility patients. CHR introduced DHEA supplementation into infertility care in 2004. Dr. Gleicher, Dr. Barad and Dr. Sen are available for additional comments.

The team plans to explore the process of follicle maturation, and especially the role of androgens in female reproduction.

Lead investigators are Aritro Sen, PhD, Research Assistant Professor, and Stephen R. Hammes, MD, PhD, Professor, both in the Division of Endocrinology and Metabolism at URSMD, who have published pioneering work on the subject in rodents.

They are joined by Norbert Gleicher, MD, CHR’s Chief Scientist, and David H. Barad, MD, MS, Senior Scientist at CHR, who revolutionized infertility treatment for women with low ovarian reserve worldwide through the introduction of DHEA.

“The goal of this research collaboration is to combine complementary animal and laboratory expertise at URSMD with clinical expertise at CHR,” explains Dr. Gleicher. “By combining research in URSMD’s unique animal model and CHR’s large clinical human experience, we aim to better understand how DHEA, as well as other androgens, improve female fertility.”

“Adds Dr. Barad. “We have known for years now that DHEA improves pregnancy chances but only recently learned that this likely occurs through conversion of DHEA to testosterone. For all practical purposes, this means that the process very likely involves the androgen receptor (AR) on granulosa cells.”

Using IUDs has a major advantage over using the Pill and condoms which is that they do not rely on using them perfectly. However, since they were first introduced, there have been health concerns surrounding their safety and whether or not they raise the risk of infertility, pelvic infection and the need to see a pelvic pain and myofascial release San Francisco expert, for example.

There are two types of IUDs, one that release copper to prevent pregnancy and another that releases the hormone progestogen. Some hormone releasing IUDS can prevent pregnancy for five years and the copper version for up to ten years.

The negative image of the IUD started back in the 1970s and 1980s when studies that were conducted on women using IUDs found that they increased risk for of pelvic inflammatory disease (PID). If left untreated PID can lead to infertility and permanent blocking of the fallopian tubes. However, further research showed the sexually transmitting infections, such as chlamydia, are actually a major cause of PID and tubal blockage, not IUDs.

To learn more about pelvic pain treatments visit this pelvic health postpartum therapy Oakland specialist website

France and Italy forbid single women and lesbian couples from using artificial insemination and in vitro fertilization to conceive. Austria and Italy ban all egg and sperm donations for IVF. Germany and Norway ban a donor egg, but not sperm.

Sweden requires that couples be together for at least a year to qualify for fertility treatment. Switzerland, among others, requires couples to be married.

And nearly everywhere in Europe except Ukraine, surrogacy is forbidden.

What this demonstrates is outdated laws. Many see placing bans on egg and sperm donation as discriminating against infertile couples.

Experts estimate thousands of Europeans travel to less restrictive countries each year to have a baby.

Reasons for the restrictions vary from country to country. Attempts to change the laws have failed. Fertility treatment remains a taboo subject in many European countries.

Germany’s history of eugenics where Nazis sterilized or euthanized people in an attempt to eliminate hereditary illnesses and handicapped people makes officials nervous about any procedures that handle embryos.

France and Italy have strong relationships with the Roman Catholic Church, which forbids IVF, primarily because the procedure may involve the destruction of embryos. The church is against artificial insemination because it believes procreation should only be by a husband and wife through the natural act of sex.

People in Western Europe who seek medical treatment elsewhere cannot be prosecuted at home even if the treatment is illegal in their own country. But there can be other complications. For example, in France, children born through surrogacy are not entitled to a French passport.

For gay and lesbian couples in France, Italy, Switzerland and elsewhere, only one partner can be the child’s legal father or mother.

Whatever the methods, whether embryo donation, or donor egg, it is clear that the laws in Europe must change with the times and to meet the demands of infertile parents who want to start or add to their family.

Both of the mediations contain a main active ingredient called finasteride which reduces male hormone activity which is also associated with side effects.

The labels on both drugs will now include a description of reported cases of male infertility that improved after patients stopped taking the drug.

The new label for the baldness medicine Propecia will include libido and other sexual disorders that continued after discontinuation of the drug.

Proscar, which treats symptoms of enlarged prostate will now have a label that adds “decreased libido that continued after discontinuation of the drug.”

Labels on the two drugs already warn of thse side effects but health officials want physicians and patients to know the problems may continue to occur even after patients stop taking the medications.

“Despite the fact that clear causal links between finasteride (Propecia and Proscar) and sexual adverse events have not been established, the cases suggest a broader range of adverse effects than previously reported in patients taking these drugs,” the FDA added.

“Therefore, prescribers and patients need to be aware of them, as part of a discussion of risk and benefits of finasteride when determining the best treatment options.”

The warning may have been influenced by reported cases of infertility treatments of men who were taking the drugs.

Canadian laws ban payments to surrogate mothers and sperm and egg donors and allow the federal government to license and regulate fertility treatments, doctors and clinics.

The HCAHR closure has drawn attention to the controversial world of assisted human reproduction in Canada that leaves infertile couples in an environment with gaping holes in legislation and regulations.

It barely got off the ground before the Supreme Court of Canada struck down sections of the Assisted Human Reproduction Act they said infringed on provincial jurisdiction.

The federal and provincial governments have yet to address the grey areas the court decision created, including the topic of embryo donation and adoption.

Canada still bans things such as human cloning and payments for sperm donors, egg donors and surrogate mothers, the courts said the provinces have the jurisdiction for health-care matters such as regulating fertility treatments and deciding how many embryos can be implanted.

The gaps have opened the door for black-market surrogacy arrangements.

While it is illegal to pay for a surrogate to carry your baby or for people to donate sperm or eggs, it is legal to pay them for out-of-pocket expenses. However, even these terms lack a clear definition.

The government feared women would be exploited — particularly poor young women — if having a baby for someone else can net a profit.

Similar sentiments were behind the decision to ban payments to sperm and egg donors, but banning the practice didn’t actually solve the problem, if there was one to solve.

The functions of the Assisted Human Reproduction Canada agency are still needed, but there is no denying the murky legislations and regulations Canada is operating.

There is no doubt among Canadians that embryo donation and egg donors should be permitted without the fuss that Canadian laws have enacted.

The launch took longer than expected, because Fertility Nutraceuticals, LLC – which developed the supplement – made unusual efforts to ensure that FERTINATAL™ DHEA for women would fulfill all of the required specifications which the product was designed for, with consistency across every tablet, according to Fertility Nutraceuticals. The required repeat rounds of quality-assurance testing at independent laboratories delayed the launch, initially scheduled for January.

“It was extremely frustrating, especially since we have seen increasing demand since we announced FERTINATAL last December,” notes Yu Kizawa, the company’s Director of Marketing and Sales. “Now, we are excited to be able to offer probably the most reliable micronized DHEA product on the market, and the only one specifically designed for women who have a difficult time conceiving.”

FERTINATAL™ was developed with strict adherence to the specifications of the Center for Human Reproduction (CHR, http://www.centerforhumanreprod.com), a research-driven fertility center in New York City that introduced DHEA supplementation for women with diminished ovarian reserve. Because of the high quality standard of FERTINATAL™, CHR, the only holder of female fertility-related U.S. patents for DHEA supplementation, endorses FERTINATAL™.

“Over-the-counter DHEA products can be very inconsistent in quality, even within the same brand,” explains Norbert Gleicher, MD, medical director of CHR. “Based on the unique quality control process of FERTINATAL™, we are confident that this new product will deliver the kind of consistency and quality we, up to this point, have been able to achieve only through pharmacy-compounded DHEA by prescription.  We, therefore, feel confident in endorsing FERTINATAL™.”

FERTINATAL™ is available for purchase at $69.50 per box (a one-month supply), online at http://www.fertinatal.com.

About Fertility Nutraceuticals, LLC
Fertiltiy Nutraceuticals, LLC, is a company specializing in nutritional supplements for women in reproductive years. The company is dedicated to developing highest-quality nutritional supplements for women with fertility problems, trying to achieve healthy pregnancies. FERTINATAL™ is the company’s first product, with additional products planned for rollout throughout 2012.

For many couples, the ordeal of several years of IVF treatment to get pregnant only to lose the baby causes enormous emotional strain. To put it mildly, it’s an emotional roller coaster.

There comes a point where it becomes apparent that the decision to accept someone else’s embryo is inevitable. After exhausting all other possibilities they begin the long journey of sourcing an donor egg.

The decision should not be taken lightly.

It’s an enormous gift from a donor, but that person needs to realize the child is not theirs; they have to look at it like it’s giving blood, and they can’t have emotional ties.

Unlike sperm donors, who have an extensive register, locating a suitable egg donor is more complicated, with some aspiring mothers resorting to newspaper ads and online forums to seek eggs.

The ideal donor needs to be below the age of 35 and finished having their own children; it is also paramount the donor understands her condition of emotional disengagement.

Many expectant parents exhaust a host of potential donors, some of who are not prepared to agree to complete disengagement. To become egg donor, a woman has to be willing to accept the reality that the child does not belong to her.

Once the hopeful couple has dealt with all their own emotions to accept they need a donor, it’s the emotional drama of having access and trying to find people to donate that proves further painstaking work.

DHEA supplementation is a relatively recent development for female infertility.

Diminished ovarian reserve occurs either due to premature ovarian aging (POA) in younger women, or as a consequence of female aging.

DHEA supplementation has demonstrated remarkable results. Many women who were told by their fertility specialist that their only chance of conception was through egg donation, have been able to conceive, with use of their own eggs, using DHEA supplements. In those women with diminished ovarian reserve, DHEA supplementation used in connection with IVF protocols has resulted in pregnancies.

DHEA treatment has gradually gained worldwide recognition and momentum. A survey in 2010 found that about a third of all IVF centers in the world were already utilizing DHEA to improve pregnancy chances in women with DOR by improving quality and quantity of eggs and embryos.

Dehydroepiandrosterone (DHEA) is an endogenous hormone — made in the human body — and secreted by the adrenal gland. DHEA serves as precursor to male and female sex hormones (androgens and estrogens). DHEA levels in the body begin to decrease after age 30. No studies on the long-term effects of DHEA have been conducted.  However, DHEA supplementation has had quite remarkable and beneficial effects rejuvenating ovarian function.

As more studies are being conducted it is recommended that expectant parents contact a fertility specialist to learn more about DHEA.